CDK4/6 inhibitors could repress immunosuppressive regulatory T cells (Tregs) and enhance effector T cells response by upregulating the level of cytokines (IL-2) in the tumor microenvironment [94]. This evidence concerns the gene CDK4 and neoplasm.